

Spotting Alzheimer's Early: Signs, Symptoms, and New Hope

June is Brain Awareness Month, a time dedicated to promoting education about brain health, neurologic disease, and the importance of early detection. This year, growing attention is being placed on Alzheimer's disease and the emergence of new treatments that may help slow progression in appropriate patients.

For many years, treatment options focused mainly on managing symptoms. Today, newer therapies such as Leqembi and Kisunla are offering new hope by targeting one of the underlying causes of Alzheimer's disease: amyloid plaque buildup in the brain.

These medications are designed for people in the early stages of Alzheimer's disease, including mild cognitive impairment (MCI) or mild dementia due to Alzheimer's. Both therapies are given through intravenous (IV) infusion and work by helping remove amyloid proteins from the brain. Clinical trials showed that these treatments may help slow cognitive decline and preserve independence for a longer period of time.

Sage Infusion is helping expand access to these innovative Alzheimer's therapies by providing infusion services and ongoing patient support in a comfortable outpatient setting.

Access to infusion centers is an important part of Alzheimer's care, especially because these medications require regular treatments and MRI monitoring. Across the country, many families face delays in accessing therapy due to shortages of specialists and infusion capacity.

Sage Infusion helps bridge this gap through a specialized program called MemoryWorkx. MemoryWorkx, is composed of compassionate, dedicated Clinical Nurse Coordinators who assist patients and families with coordinating referrals and appointments, streamlining communication between your doctors, ensuring timely access to services such as MRI's, and navigating insurance and assistance programs. Alzheimer's can feel overwhelming, but

you do not have to face it alone, Sage Infusion's MemoryWorkx team allows for improved quality of care and ensures no step is missed.

Brain Awareness Month also serves as an important reminder that early diagnosis matters. Both Leqembi and Kisunla are intended for people in the earliest symptomatic stages of Alzheimer's disease, before significant brain damage has occurred. Recognizing symptoms early may create opportunities for treatment, planning, and support.

Common early warning signs can include: Increasing short-term memory loss, repeating questions or conversations, difficulty managing finances or medications, trouble finding words, changes in judgment or organization, getting lost in familiar places, personality or mood changes. If these symptoms are present, patients and families should speak with their provider or neurologist about cognitive screening.

Many patients delay evaluation because they believe memory loss is simply part of normal aging. However, experts increasingly emphasize that earlier detection leads to better opportunities for treatment and care planning.

While Leqembi and Kisunla are not cures, they represent a major advancement in Alzheimer's treatment by addressing disease biology rather than symptoms alone. For many families, even slowing progression may mean more time for meaningful conversations, independence, and quality of life.

During Brain Awareness Month, healthcare providers, patients, and caregivers are encouraged to start conversations about memory health, recognize early symptoms, and explore whether advanced screening or treatment options may be appropriate. As awareness grows and access improves through providers like Sage Infusion, more patients may benefit from therapies that are changing the future of Alzheimer's care.